secwatch.observer — SEC 8-K summary
======================================

Issuer:     Travere Therapeutics, Inc. (TVTX)
CIK:        0001438533
Form:       8-K
Filed at:   2025-01-13T23:59:59+00:00
Accession:  0001438533-25-000002
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Travere reports ~$74M preliminary Q4 net product sales; FILSPARI PSFs up 40% QoQ
--------------------------------------------------------------------------------

- Preliminary Q4 2024 FILSPARI net sales ~$50M; total Q4 net product sales ~$74M; FY2024 ~$227M.
- Received 693 new FILSPARI patient start forms in Q4, a 40% sequential increase in net sales vs Q3.
- Cash, equivalents and marketable securities ~$371M at year-end 2024.
- FDA accepted sNDA to modify liver monitoring for FILSPARI in IgAN; PDUFA date Aug 28, 2025.
- On track for FSGS regulatory pathway update by Q4 2024 earnings call; partner CSL Vifor milestone $17.5M upon European full approval.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1438533/000143853325000002/0001438533-25-000002-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1438533/000143853325000002/tvtx-20250113.htm
  HTML page:      https://secwatch.observer/filing/0001438533-25-000002

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer